

CONTENTS

CHAPTER 1		1-12
	GENERAL INTRODUCTION	
CHAPTER 2		13-90
	REVIEW OF LITERATURE	
2.1	Disease Burden	13-16
2.1.1	Disease Burden: Globe	
2.2.2	Disease Burden: India	
2.2	The Disease Diabetes	17-20
2.3	Pathophysiology of Diabetes	21-22
2.3.1	Type 1 Diabetes	
2.3.2.	Type 2 Diabetes	
2.3.3.	Gestational Diabetes (GDM)	
2.3.4.	Maturity Onset Diabetes of the Young (MODY)	
2.4	Diagnosis of Diabetes	22-23
2.5	Complication of Type 2 Diabetes	23-26
2.5.1	Diabetic Nephropathy	
2.5.2.	Diabetic Retinopathy (DR)	
2.5.3	Diabetic Neuropathy	
2.5.4.	Macrovascular Complications of Diabetes:	
	Cardiovascular Disease	
2.5.5	Cerebrovascular Disease	
2.6	Diabetic Therapy	27-27
2.7	Diabetic Nephropathy	27-32
2.7.1	Disease Burden and Epidemiology	
2.7.2	Pathology and Diagnosis of DN	
2.8	Anatomical and Structural Changes of Glomeruli in Diabetes	32-33
2.9	Classification of Diabetic Nephropathy	33-38
2.9.1	Class I: Glomerular Basement Membrane Thickening.	
2.9.2	Class II: Mesangial Expansion, Mild (IIa) or Severe	

	(IIb).	
	2.9.3 Class III: Nodular Sclerosis (Kimmelstiel– Wilson lesions)	
	2.9.4 Class IV: Advanced Diabetic Glomerulosclerosis	
	2.9.5 Tubulointerstitial and Vascular Lesions in DN	
2.10	Therapy for DN	37-38
2.11	Risk Factor for Diabetic Nephropathy	38-39
2.12	Pathways involved in the pathogenesis of DN	39-45
	2.12.1 Hyperglycemia increase superoxide production and role of oxidative stress in DN	
	2.12.2 Polyol pathway	
	2.12.3 Advanced Glycation End Products (AEG) pathway	
	2.12.4 Protein kinase C pathway	
	2.12.5 Hexosamine Pathway	
	2.12.6 Inflammatory Pathways of DN	
2.13	Inflammasome Complex	45-54
	2.13.1 The NLR Family	
	2.13.2 NLR family pyrin domain containing 3(NLRP3)	
	2.13.3 NLRP3 gene function	
	2.13.4 CASPASE1	
	2.13.5 General function and association with disease	
	2.13.6 PYCARD	
	2.13.7 Functions of PYCARD and association with disease	
2.14	Toll Like Receptors and inflammation	55-60
	2.14.1 Toll Like Receptors (TLRs)	
	2.14.2 Cellular Localization of TLRs and Cell-Specific Expression	
	2.14.3 TLR Signaling Pathways	
2.15	Inflammatory cytokines: Interleukin 1 β (IL1 β), Interleukin 18 (IL18) and Tumor Necrosis Factor α (TNF α)	60-64
	2.15.1 Interleukin 1beta (IL1 β)	
	2.15.2 Interleukin 18 (IL18)	
	2.15.3 Tumour Necrosis Factor alpha (TNF α)	

2. 16	Damage-associated molecular patterns (DAMPs)	64-69
	2.16.1 DAMP mediated Inflammasome activation	
	2.16.2 DAMP mediated TLRs activation	
2. 17	Non coding RNAs: Overview	69-85
	2.17.1 Micro RNAs	
	2.17.1.1 Biogenesis, structure and functions of miRNA	
	2.17.1.2 miRNA-mediated silencing	
	2.17.1.3 Location of mature miRNA	
	2.17.1.4 Association of miRNA with disease	
2.18	Human gut microbiome	85-90
	2.18.1: Human gut microbiome and disease	
	2.18.2: Human gut microbiome and host immunity	
CHAPTER 3		91-93
AIMS AND OBJECTIVES		
3.1	Research question(s)/hypothesis:	91-92
3.2	Objectives of the Study	92-93
CHAPTER 4		94-128
MATERIAL AND METHODS		
4.1	Study design	94
4.2	Site sites	95
4.3	Ethical approval to recruit study subjects	95
4.4	Recruitment of cases and controls	95-98
	4.4.1 Diagnosis of Diabetes case	
	4.4.2 Diagnosis of DN	
4.5	Inclusion Criteria:	98
4.6	Exclusion criteria	98
4.7	Collection of socio-demographic and baseline information	98-99
4.8	Sample collection and preparation for analysis	99
	4.8.1 Procedure	
4.9	Total RNA isolation from PBMC	100-101
	4.9.1 Procedure	
4.10	Quantification of total RNA	101-102

4.10.1 Procedure	
4.11 Preparation of c-DNA from eluted RNA	102-103
4.11.1 Procedure	
4.12 Real Time PCR for mRNA expression assay	104-109
4.12.1 Introduction	
4.12.2 Procedure for real time PCR	
4.13 Reverse Transcription and Real Time PCR for miRNA expression assay	109-113
4.13.1 miRNA selection	
4.13.2 Reverse Transcription for miRNA expression assay	
4.13.3 Real Time PCR for mi-RNA expression assay	
4.13.4 Procedure of real-time PCR	
4.14 Calculation of relative quantification	113-114
4.15 Cell Culture Technique for Validation of miRNA-mRNA Interaction for The Proposed Study:	114-118
4.15.1 Principle	
4.15.2 Subculture of INT407 Cell line	
4.15.3 Cell counting	
4.15.3.1 Procedure	
4.15.4 Cryopreservation of cell lines	
4.15.4.1 Principle	
4.15.4.2 Procedure	
4.15.5 Induction of Glucose in Cultured cells	
4.16 Estimation of IL1 β , IL18 and TNF α by commercially available ELISA kit	119-123
4.16.1 Estimation of IL1 β	
4.16.1.1 Procedure	
4.16.1.2 Calculation of results	
4.16.1.3 Sensitivity and reproducibility and specificity of the IL1 β ELISA kit	
4.16.2 Estimation of IL18	
4.16.2.1 Procedure	
4.16.2.2 Calculation of results	

4.16.2.3	Sensitivity and reproducibility and specificity of the IL18 ELISA kit	
4.16.3	Estimation of TNF α	
4.16.3.1	Procedure	
4.16.3.2	Calculation of results	
4.16.3.3	Sensitivity and reproducibility and specificity of the TNF α ELISA kit	
4.17	Estimation of Gut microbiota from studied participants	123-128
4.17.1	Methodology for DNA isolation from stool samples for gut microbiota estimation from studied participants	
4.17.1.1	Procedure	
4.17.2	16S Metagenome Sequencing	
4.17.2.1	Gene-specific sequences	
4.17.2.2	Metagenominc sequence Analysis	
4.18	Statistical Analysis	128
CHAPTER 5		129-195
	RESULTS	
5.1	Distribution of Demographic and clinical variables of study subjects	129-133
5.2	Expression of mRNA for NLRP3, CASP-1 and PYCARD in peripheral blood mononuclear cells (PBMC) among cases and controls:	134-135
5.3	Expression of miRNA hsa-miR 223, hsa-miR 22-3p, hsa-miR4291 and hsa-miR 185-3p in PBMC from DN, DC and HC study population.	136-138
5.4	Expression of m-RNA for TLRs (TLR1-10) in PBMC among diabetics and controls:	138-141
5.5	Expression of hsa-miR-561-3p, hsa-miR-4307, hsa-miR-448 and hsa-miR-4760-3p in PBMC from Type2 DN patients, DC and HC study subjects.	141-143
5.6	Expression of m-RNA for cytokines IL1 β , IL18 and TNF- α in PBMC among diabetics and controls	143-146
5.7	Linear regression of relative quantification of	146-148

- Inflammasome complex mRNA that includes NLRP3, CASP-1 and PYCARD for DN severity based on estimated glomerular filtration rate (eGFR).
- 5.8 Linear regression of relative quantification of hsa-miR-223, 149
 hsa-miR-22-3p, hsa- miR-4291 and hsa-miR-185-3p
 miRNAs targets Inflammasome complex mRNA with DN
 severity based on eGFR.
- 5.9 Linear regression of relative quantification of TLR m-RNA 150-153
 that includes TLR1, TLR2, TLR3, TLR4, TLR5, TLR6,
 TLR7, TLR8, TLR9 and TLR10 for DN severity based on
 estimated glomerular filtration rate (eGFR).
- 5.10 Linear regression of relative quantification of hsa-miR-561- 153-154
 3p, hsa-miR-4307, hsa-miR-448 and hsa-miR-4760-3p
 miRNAs targets TLRs with DN severity based on eGFR
- 5.11 Linear regression of relative quantification of inflammatory 154-155
 cytokines IL1 β , IL18 and TNF α with DN severity based on
 eGFR
- 5.12 Correlation of mRNAs and its targeted mi-RNA expression 155-164
 among study subjects
- 5.13 Distribution of IL1 β , IL18 and TNF- α from plasma of HC, 165-166
 DC and DN patients
- 5.14 Linear regression of plasma IL1 β , IL18 and TNF α cytokine 166
 with DN severity based on estimated glomerular filtration
 rate (eGFR).
- 5.15 Validation of miRNA-mRNA interaction in INT407 cell 167-173
 lines
- 5.15.1 Expression of Inflammasome complex gene includes
 NLRP3, CASP-1 and PYCARD in INT407 cells upon
 induced with different concentration of glucose
- 5.15.2 Expression of miRNAs includes hsa-miR-223, hsa-
 miR-22-3p, hsa- miR-4291 and hsa-miR-185-3p targets
 NLRP3, CASP-1 and PYCARD genes in INT407 cells upon
 induced with different concentration of glucose.

5.15.3	Expression of m-RNA for TLRs (TLR1-10) in INT407 cells upon induced with different concentration of glucose.	
5.15.4	Expression of miRNAs includes hsa-miR-561-3p, hsa-miR-4307, hsa-miR-448 and hsa-miR-4760-3p targets TLRs genes in INT407 cells upon induced with different concentration of glucose	
5.15.5	Expression of IL1 β , IL18 and TNF α genes in INT407 cells upon induced with different concentration of glucose.	
5.16	Expression of NLRP3, CASP-1, TLR4 and TLR7 form single cell expression experiment and network analysis of studied genes of inflammation cascade	174-178
5.17	Microbial architecture of study subjects	179-196
CHAPTER 6		197-219
	DISCUSSION	
CHAPTER 7		
	CONCLUSION AND FUTURE PROSPECTS	220-225
CHAPTER 8		
	BIBLIOGRAPHY	226-275
Appendix 1	Abbreviations Used	276-277
Appendix 2	Bio-data	278-288
Appendix 3	Transcript of the Ph. D. Course Work	289
Appendix 4	List of Publications	290-291
Appendix 5	Ethical Clearance certificate	292
Appendix 6	Awards and Honors	293
Appendix 7	Socio demographic and clinical information sheet and Patients Consent Form	294-297

LISTS OF FIGURES

Figure No.	Description	Page No.
2.1	Global prevalence of diabetes estimated in 2017 inner circle and predicted for 2045 in outer circle	15
2.2	Burden of diabetes in India	16
2.3	The Blue circle: universal symbol for diabetes	19
2.4	Sign and symptom of diabetes	20
2.5	Complications of Type 2 diabetes	24
2.6	Staging of chronic kidney disease	32
2.7	Morphology and structural changes in normal and diabetic kidney glomerulus	33
2.8	Morphologic lesions in DN	35
2.9	Pathologic classification of DN based on glomerular changes	36
2.10	Various therapeutic agents identified in the metabolic and alternative pathways of DN	38
2.11	Various pathways involve in the pathogenesis of DN	40
2.12	Hyperglycemia mediated activation of various pathways for the progression of DN	42
2.13	Inflammatory pathway in DN and schematic summary of the therapeutic targets	45
2.14	Represents the Human and Mouse NLR Family Members	47
2.15	Chromosomal position of NLRP3 protein (1q44)	48
2.16	Gene tree of NLRP3	49
2.17	Differential expression of NLRP3	49
2.18	Assemble and activation of NLRP3 Inflammasome	50
2.19	Chromosomal location of CASP1 gene	52
2.20	Gene tree of CASP1	52
2.21	Chromosomal location of PYCARD	53
2.22	Gene tree of PYCARD	54
2.23	History of Toll Like Receptors related significant achievements	56

2.24	Evolutionary relationships of all 10 human TLRs	56
2.25	Structure of TLRs	57
2.26	Toll-like receptor (TLR) protein structure, location and amino acid variations with Gene Bank Accession numbers.	58
2.27	TLR signaling pathways	60
2.28	Chromosomal location of IL1 β	61
2.29	Chromosomal location of IL18	62
2.30	Chromosomal location of TNF α	63
2.31	List of DAMPs and their receptors	65
2.32	DAMP associated activation of immune response	66
2.33	The NLRP3 Inflammasome activation through mitochondrial reactive oxygen specie	68
2.34	Types of non coding RNAs	70
2.35	Generation of miRNA	72
2.36	Structure of miRNA genes. (a) intronic miRNAs in coding transcription units (TUs), for example, the mir-101-2 cluster (b) Intronic miRNAs in noncoding TU, such as the mir-135a-2 cluster (c) Exonic miRNAs in coding TU (d) Exonic miRNAs in noncoding TU	73
2.37	Biogenesis and function of miRNA	75
2.38	Mechanism of action of miRNA	77
2.39	Mechanisms of miRNA-Mediated Gene Silencing	79
2.40	Figure represents the crosstalk between microbes and host	89
4.41	Image of INT407 cells	116
4.42	Induction of glucose on INT407 cells	118
5.43	Distribution of Demographic and clinical variables among study subjects. [A]Weight of the study population significantly higher among HC subjects than DC and DN. [B] Distribution of BMI among HC was significantly higher than DC and DN. [C] Duration of Diabetes (DOD) was significantly higher in DN than DC.[D]Random blood sugar (RBS) in mg/dl was higher in DC than DN and HC. [E]Serum creatinine level (mg/dl) was significantly higher in DN subjects compared toDC and HC. [F]Distribution of Serum urea level (mg/dl) of the study populationrevealed that DN subjects has significantly higher S.	133

	creatinine than DC and HC. All data is presented as mean±SD and significant level was determined by P<0.05..	
5.44	Melting curves results of GAPDH, NLRP3, CASP-1 and PYCARD expression in SYBR green based realtime PCR. A single melting peak correspond to each amplicon generated using specific set of primers.	134
5.45	Gene expression of NLRP3, CASP-1 and PYCARD from DC and DN patients after normalizing to HC as reference subjects. Bars represent the mean relative expression of gene ± SD of [A] NLRP3 [B] CASP-1 and [C] PYCARD gene expression in PBMC from DC and DN patients (n = 60 per group). m-RNA expression (fold change) of [A] NLRP3, p=0.009 and [B] CASP-1, P _{mw} =0.02 were significantly higher among DN subjects than DC subject. P value considered significant at P< 0.05, P< 0.01 and P< 0.001 between DC and DN.	135
5.46	Melting curves results of miRNA, hsa-miR-223 and hsa-miR-22-3p targeting NLRP3, hsa-miR-4291 targeting CASP-1 and hsa-miR-185-3p targeting PYCARD expression in SYBR green based realtime PCR. A single melting peak corresponds to each amplicon generated using specific set of primers for each miRNA.	136
5.47	mi-RNA expression of hsa-miR-223, hsa-miR-22-3p, hsa-miR-4291 and hsa-miR-185-3p from DC and DN patients after normalized to HC as reference subjects. Bars represents the mean relative expression of miRNA± SD [A] hsa-miR-223, [B] hsa-miR-22-3p, [C] hsa-miR-4291 and [D] hsa-miR-185-3p expression in PBMC from DC and DN patients (n = 60 per group). Expression (fold change) of [D] hsa-miR-185-3p targeting PYCARD was significantly (P _{mw} =0.04) high among DN subjects compared to DC.	137- 138
5.48	Melting curves results of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9 and TLR10 mRNA expression in SYBR green based realtime PCR. A single melting peak corresponds to each amplicon generated using specific set of primers for each mRNA.	139
5.49	Gene expression of TLR1-10 from DC and DN patients after normalized to HC as reference subjects. Bars represent the relative expression of gene ± SD of (A) TLR1 (B) TLR2 (C) TLR3 (D) TLR4	140

	(E)TLR5 (F) TLR6 (G)TLR7 (H)TLR8 (I) TLR9 and (J)TLR10 gene expression in PBMC from DC and DN patients (n = 60 per group). mRNA expression (fold change) of TLR4 (D) was significantly (p=0.04) elevated among DN subjects than in DC subjects. P value considered significant at P< 0.05, P< 0.01 and P< 0.001 between DC and DN.	
5.50	Melting curves results of hsa-miR-561-3p, hsa-miR-4307, has-miR-448 and hsa-miR-4760-3p miRNA expression in SYBR green based realtime PCR. A single melting peak corresponds to each amplicon generated using specific set of primers for each miRNA.	141
5.51	miRNA expression of hsa-miR-561-3p, hsa-miR-4307, hsa-miR-448 and hsa-miR-4760-3p from HC, DC and DN patients after normalizing to HC as reference subjects. Bars represents the mean relative expression of miRNA± SD [A] hsa-miR-561-3p [B] hsa-miR-4307 [C] hsa-miR-448 and [D] hsa-miR-4760-3p expression in PBMC from DC and DN patients (n = 60 per group). Expression (fold change) of (C) hsa-miR-448 targeting TLR4 was significantly ($P_{mw}=0.01$) high among DN subjects compared to among DC. P value considered significant at P< 0.05, P < 0.01 and P< 0.001 between DC and DN of miRNAs.	142
5.52	Melting curves results of IL1 β , IL18 and TNF- α mRNA expression in SYBR green based realtime PCR. A single melting peak corresponds to each amplicon generated using specific set of primers for each mRNA.	144
5.53	mRNA expression of cytokines IL1 β , IL18 and TNF- α from DC and DN patients after normalizing to HC as reference subjects. Bars represents the mean relative expression of mRNA± SD [A] IL1 β [B] IL18 and [C] TNF- α expression in PBMC from DC and DN patients (n = 60 per group). Expression (fold change) of [A] IL1 β was significantly ($P_{mw}=0.03$) high among DC subjects compared to among DN. P value considered significant at P< 0.05, P< 0.01 and P< 0.001 between DC and DN of mRNAs.	145
5.54	Figure represents the linear regression of the interaction of NLRP3 gene expression with eGFR among the Type2 Diabetic subjects. Elevated level of NLRP3 associated with reduced eGFR level (P:0.05). The estimate of the regression is -0.77 with the SE:0.39. Residual standard	147

	error: 91.92, Multiple R-squared: 0.06, Adjusted R-squared: 0.048	
5.55	Figure represents the linear regression of the interaction of CASP-1 gene expression with eGFR among the Type2 Diabetic subjects. Elevated level of CASP-1 associated with reduced eGFR level (P:0.04). The estimate of the regression is -2.16 with the SE:1.02. Residual standard error: 87.62, Multiple R-squared: 0.07, Adjusted R-squared: 0.06	148
5.56	Figure represents the linear regression of the interaction of TLR4 gene expression with eGFR among the Type2 Diabetic subjects. Elevated level of TLR4 associated with reduced eGFR level (P:0.04). The estimate of the regression is -1.38 with the SE:0.66. Residual standard error: 90.69, Multiple R-squared: 0.1, Adjusted R-squared: 0.08	151
5.57	Figure represents the linear regression of the interaction of TLR7 gene expression with eGFR among the Type2 Diabetic subjects. Elevated level of TLR7 associated with eGFR level (P: 0.008). The estimate of the regression is 0.45 with the SE: 0.15. Residual standard error: 83.19, Multiple R-squared: 0.3, Adjusted R-squared: 0.2	152
5.58	Figure represents the regression of NLRP3 expression with the hsa-miR-223 expression. NLRP3 expression inversely related with hsa-miR-223 with an estimate -0.21 with the SE: 0.3, Residual standard error: 28.76, Multiple R-squared: 0.01, Adjusted R-squared: -0.01,P:0.05	156
5.59	Figure represents the regression of NLRP3 expression with the hsa-miR-22-3p expression. NLRP3 expression was positively related with hsa-miR-223 expression. The estimate of regression was 0.8, SE: 1.3, Residual standard error: 28.64, Multiple R-squared: 0.007, Adjusted R-squared: -0.007,P:0.5	157
5.60	Figure represents the regression of CASP-1 expression with its targeting miRNA, has-miR-4291 expression. CASP-1 expression was positively related with has-miR-4291 expression. The estimate of regression was 0.004, SE: 0.03, Residual standard error: 11.36, Multiple R-squared: 0.00003, Adjusted R-squared: -0.01, P: 0.9.	158
5.61	Figure represents the regression of PYCARD expression with its	159

	targeting miRNA, has-miR-185-3p expression. PYCARD expression was inversely related with has-miR-185-3p expression. The estimate of regression was -0.0005 with the SE: 0.001, Residual standard error: 83.05, Multiple R-squared: 0.002, Adjusted R-squared: -0.01, P: 0.7	
5.62	Figure represents the regression of TLR2 expression with its targeting miRNA, hsa-miR-561-3p expression. TLR2 expression was positively related with hsa-miR-561-3p expression. The estimate of regression was 0.31 with the SE: 0.2, Residual standard error: 9.09, Multiple R-squared: 0.1, Adjusted R-squared: 0.09, P: 0.1	160
5.63	Figure represents the regression of TLR3 expression with its targeting miRNA, hsa-miR-4307 expression. TLR3 expression was positively related with hsa-miR-4307 expression. The estimate of regression was 45.72, with the SE: 51.54, Residual standard error: 169.8, Multiple R-squared: 0.07, Adjusted R-squared: -0.02, P: 0.4.	161
5.64	Figure represents the regression of TLR4 expression and the hsa-miR-448 expression. TLR4 expression inversely related with hsa-miR-448 but the association was insignificant (P: 0.8). The estimate of regression was -0.03, SE: 0.17, Residual standard error: 23.25, Multiple R-squared: 0.001, Adjusted R-squared: -0.03.	162
5.65	Figure represents the regression of TLR7 expression and the hsa-miR-4760-3p expression. TLR7 expression positively related with hsa-miR-4760-3p but the association was insignificant (P: 0.1). The estimate of regression was 70.06, SE: 40.70, Residual standard error: 121.1, Multiple R-squared: 0.2, Adjusted R-squared: 0.1.	163
5.66	Figure represents the distribution of plasma level of cytokines IL1 β , IL18 and TNF- α from HC, DC and DN patients. Bars represents the plasma level of [A] IL18 [B] IL1 β and [C] TNF- α as mean \pm SD (n = 60 per group). Statistically significant difference observed for IL18 level which was higher in DN (1957 \pm 771.0 pg/ml) and DC (1247 \pm 624.5 pg/ml) compared to HC (930.6 \pm 480.9 pg/ml), (P _{ANOVA} < 0.0001). Significantly higher plasma level of IL18 was observed among DN patients than DC (P _{TUKEY'S} < 0.0001). P value considered significant at p < 0.05, p < 0.01 and p < 0.001.	165

5.67	Figure represents the relative quantification of Inflammasome complex gene expression in INT407 cell upon glucose induction. [A] NLRP3, [B] CASP-1 and [C] PYCARD gene was upregulated in INT407 cells induced with different concentration of glucose compared to untreated cells.	168
5.68	Figure represents the relative quantification of miRNAs targets Inflammasome complex gene expression in INT407 cell upon glucose induction. [A] hsa-miR-223 was upregulated gradually with higher glucose concentration. [B] hsa-miR-22-3p, [C] hsa-miR-4291 and [D] hsa-miR-185-3p miRNA was downregulated in INT407 cells induced with different concentration of glucose compared to UT.	169
5.69	Figure represents the relative quantification of TLRs gene expression in INT407 cell upon glucose induction.	171
5.70	Figure represents the relative quantification of miRNAs targets TLRs in INT407 cell upon glucose induction. [A] hsa-miR-561-3p was upregulated with higher glucose concentration. [B] hsa-miR-4307 and [C] hsa-miR-448 was upregulated in cells treated with 125mg/dl glucose. [D] hsa-miR-4760-3p miRNA was downregulated in INT407 cells induced with different concentration of glucose compared to UT.	172
5.71	Figure represents the relative quantification of IL1 β , IL18 and TNF α genes gene expression in INT407 cell upon glucose induction. [A] IL1 β was upregulated gradually with higher glucose concentration. [B] IL18 expressed highly in cells treated with 125mg/dl glucose, [C] TNF α expression shows downregulation in cells cultured with 500mg/dl glucose.	173
5.72	Expression of NLRP3, CASP-1, TLR4 and TLR7 form single cell expression experiment of Pancreatic Islets cells from healthy and T2DM patients	175
5.73	Expression of NLRP3, CASP-1, TLR4 and TLR7 form single cell expression experiment of Immune cells	176
5.74	Expression of NLRP3, CASP-1, TLR4 and TLR7 form single cell expression experiment from organs and tissues from individual mice	177

5.75	Insilico net work analysis were done by Gene mania to understand the interaction like physical interactions, co-expression, prediction, co-localization, pathways, genetic interactions and shared protein domains between [A] NLRP3 Inflammasome, TLRs ,TNF α , IL1 β , IL18 and other inflammatory molecules [B] NLRP3 and other inflammatory molecules [C] TLR4 and other inflammatory molecules	178
5.76	Bacterial abundance of Phylum among study individuals	179
5.77	Represents the abundance of <i>Actinobacteria</i> , <i>Bacteroidetes</i> , <i>Firmicutes</i> and <i>Proteobacteria</i> in HC, DC and DN subjects. [A] Abundance of <i>Actinobacteria</i> is significantly lower in DN (0.19 \pm 0.31) than HC (3.07 \pm 3.37) subjects. B] Abundance of <i>Proteobacteria</i> is significantly increased in DN (41.36 \pm 14.66) than HC (9.84 \pm 7.67), p<0.05. Statistically significant was considered P<0.05, P<0.001 & P<0.0001	180
5.78	Bacterial abundance of Class among study individuals	181
5.79	Bacterial abundance of Order among study individuals	181
5.80	Bacterial abundance of Family among study individuals	182
5.81	Represents the abundance of <i>Escheichia</i> among HC, DC and DN study participants. Abundance of <i>Escherichia</i> significantly increased in DN subjects than HC and DC. Statistically significant difference for abundance of <i>Escherichia</i> observed between HC (0.18 \pm 0.25) and DN (32.53 \pm 16.84), P<0.01.	183
5.82	Figure represents the linear regression of the interaction of <i>Escherichia</i> with the NLRP3 gene expression among the Type2 Diabetic subjects. Elevated level of <i>Escherichia</i> associated with increased NLRP3 expression (P:0.0004). The estimate of the regression is 1.64 with the SE:0.33. Residual standard error: 16.04, Multiple R-squared: 0.53, Adjusted R-squared: 0.50 , F-statistic: 25.47	186
5.83	Figure represents the linear regression of the interaction of <i>Escherichia</i> with the CASP1 gene expression among the Type2 Diabetic subjects. Elevated level of <i>Escherichia</i> associated with increased CASP1 expression (P:0.0009). The estimate of the regression is 1.04 with the SE:0.27. Residual standard error: 18.26, Multiple R-squared: 0.37, Adjusted R-squared: 0.35, F-statistic: 14.38	187

5.84	Figure represents the linear regression of the interaction of <i>Escherichia</i> with the phylum <i>Bacteroidetes</i> among the Type2 Diabetic subjects. Elevated level of <i>Escherichia</i> associated with decreased <i>Bacteroidetes</i> (P:0.03). The estimate of the regression is -0.75 with the SE:0.33. Residual standard error: 20.98, Multiple R-squared: 0.17, Adjusted R-squared: 0.1, F-statistic: 5.08.	188
5.85	Figure represents the linear regression of the interaction of <i>Escherichia</i> with the genus <i>Acinetobacter</i> among the Type2 Diabetic subjects. Elevated level of <i>Escherichia</i> associated with increased <i>Acinetobacter</i> (P:0.001). The estimate of the regression is 5.56 with the SE:1.52. Residual standard error: 18.43, Multiple R-squared: 0.37, Adjusted R-squared: 0.34, F-statistic: 13.47.	189
5.86	Figure represents the linear regression of the interaction of <i>Escherichia</i> with the genus <i>Wautersiella</i> among the Type2 Diabetic subjects. Elevated level of <i>Escherichia</i> associated with increased <i>Wautersiella</i> (P:0.0009). The estimate of the regression is 2.29 with the SE:0.61. Residual standard error: 18.22, Multiple R-squared: 0.38, Adjusted R-squared: 0.36, F-statistic: 14.31.	190
5.87	Figure represents the linear regression of the interaction of <i>Escherichia</i> with the genus <i>Prevotella</i> among the Type2 Diabetic subjects. Elevated level of <i>Escherichia</i> associated with decreased <i>Prevotella</i> (P:0.04). The estimate of the regression is -0.48 with the SE:0.23. Residual standard error: 21.2, Multiple R-squared: 0.16, Adjusted R-squared: 0.12, F-statistic: 4.49.	191
5.88	Figure represents the linear regression of the interaction of <i>Escherichia</i> with the eGFR status among the Type2 Diabetic subjects. Elevated level of <i>Escherichia</i> associated with decreased eGFR status (P:0.02). The estimate of the regression is -0.2 with the SE:0.08. Residual standard error: 20.63, Multiple R-squared: 0.20, Adjusted R-squared: 0.17, F-statistic: 6.08	192
5.89	Bray-Curtis diversity index (BCDI) of inter and intra group of study subjects. BCID reveals larger inter-individual distance among the DN whereas BCDI significantly reduced for HC and DC. (A) Intergroup	195

	BCDI significantly significantly higher among diabetic subjects (DC and DN) compared to HC ($P < 0.0001$). (B) Intra individual BCDI was higher in HC/DN and DC/DN than HC/ DC	
5.90	Frequency of genus in Gut microbiota among study subjects	196
5.91	Principal component analysis of Diabetic and non diabetic subjects	196

LISTS OF TABLES

Table No.	Description	Page No.
2.1	Global estimation of Diabetes: Estimated from 2017 and predicted for 2045	14
2.2	Nobel Prize in the field of diabetes related work	17-18
2.3	Criteria for the diagnosis of diabetes	23
2.4	Epidemiology of diabetic nephropathy	28
2.5	Diagnosis and main clinical characteristics of Diabetic nephropathy based on urine albumin excretion	29
2.6	Severity and diagnosis of DN according to Glomerular Filtration Rate and the clinical renal manifestation.	31
2.7	Scoring system of interstitial and vascular lesions of DN	37
2.8	The most relevant web-based tools for miRNA sequence-based prediction.	81-82
2.9	List of miRNAs involved in Vascular complications	83-84
2.10	Highly-abundant bacterial species in different disease conditions	87
4.10	ADA/ICMR guidelines for diagnosis of diabetes and intermediate hyperglycaemia	96
4.11	Diabetic nephropathy diagnosis and main clinical characteristics based on urine albumin excretion	97
4.12	Severity and stages of DN according to GFR (ml/min/1.73m ²)	98
4.13	Spectrophotometer reading of total RNA	102
4.14	Genomic DNA elimination reaction components	103
4.15	Reverse transcription reaction components	104
4.16	Primers used for the detection of expression level for the targeted genes and housekeeping gene	105-107
4.17	Preparation of reaction mix for real-time PCR for mRNA expression	108
4.18	The amplification protocol of real-time PCR for mRNA	109

	expression	
4.19	List of miRNA and their target genes with target score from miRDB	110
4.20	Preparation of reverse-transcription master mix for cDNA synthesised	111
4.21	Reaction setup for real-time PCR	112
4.22	Thermal cycling conditions for real-time PCR	113
5.23	Distribution of Demographic and clinical variables of study subjects	131-132
5.24	Relative quantification of Inflammasome complex and their targeting miRNA expression from Diabetic Control and Diabetic Nephropathy patients taking healthy subjects as reference.	138
5.25	Relative quantification of TLRs and their targeting miRNA expression from DC and DN patients taking healthy subjects as reference.	143
5.26	Relative quantification of cytokines IL1 β , IL18 and TNF- α expression from Diabetic Control and Diabetic Nephropathy patients taking healthy subjects as reference subject.	145
5.27	Linear regression of relative quantification of Inflammasome complex m-RNA that includes NLRP3, CASP-1 and PYCARD for DN severity based on estimated glomerular filtration rate (eGFR).	148
5.28	Linear regression of relative quantification of hsa-miR-223, hsa-miR-22-3p, hsa- miR-4291 and hsa-miR-185-3p miRNAs targets Inflammasome complex mRNA with DN severity based on eGFR.	149
5.29	Linear regression of relative quantification of TLR m-RNA that includes TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9 and TLR10 for DN severity based on estimated glomerular filtration rate (eGFR).	153
5.30	Linear regression of relative quantification of hsa-miR-561-3p, hsa-miR-4307, hsa-miR-448 and hsa-miR-4760-3p	154

	miRNAs targets TLRs with DN severity based on eGFR.	
5.31	Linear regression of relative quantification of inflammatory cytokines IL1 β , IL18 and TNF α with DN severity based on eGFR	155
5.32	Correlation of mRNAs and its targeted mi-RNA expression among study subjects	164
5.33	Linear regression of plasma IL1 β , IL18 and TNF α cytokine with DN severity based on estimated glomerular filtration rate (eGFR).	166
5.34	Bacterial abundance of Genus <i>Acinetobacter</i> , <i>Bacteroides</i> , <i>Bifidobacterium</i> , <i>Dialister</i> , <i>Escherichia</i> , <i>Faecalibacterium</i> , <i>Lactobacillus</i> , <i>Prevotella</i> and <i>Wautersiella</i> among HC, DC and DN study subjects	184
5.35	Bacterial abundance of <i>Gammaproteobacteria</i> (Class), <i>Enterobacteriales</i> (Order), <i>Enterobacteriaceae</i> (Family) and <i>Escherichia</i> (Genus) among HC, DC and DN study subjects	185
5.36	Linear regression to predict the relative abundance of phylum, gene expression and clinical parameters with the genus <i>Escherichia</i>	193
5.37	Represents the Operational Taxonomic Units (OUT) and Alpha diversity (Shannon -diversity-index and Simpson) among HC, DC and DN study subjects	194
5.38	Bray-Curtis dissimilarity index among intra-group and intergroup of study plot	194
